← Eichor
Study identifier: NCT02905565 Synced from ClinicalTrials.gov · July 27, 2026
● Completed

NBP in Adult Patients With Acute Ischemic Stroke (AIS)

Condition: AIS  ·  Sponsor: CSPC-NBP Pharmaceutical Co., Ltd.

PhasePhase 2
Planned participants177
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

This is a Phase 2 multicenter, randomized, double-blind, placebo-controlled, add-on to standard of care study of NBP softgel capsules for the treatment of mild to moderate AIS in adults.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (21)

Investigative SiteLos Angeles, California, United States
Investigative SiteLos Angeles, California, United States
Investigative SiteJacksonville, Florida, United States
Investigative SiteDes Moines, Iowa, United States
Investigative SiteLouisville, Kentucky, United States
Investigative SiteBoston, Massachusetts, United States
Investigative SiteGolden Valley, Minnesota, United States
Investigative SiteSt Louis, Missouri, United States
Investigative SiteOmaha, Nebraska, United States
Investigative SiteBuffalo, New York, United States
Investigative SiteAsheville, North Carolina, United States
Investigative SiteColumbus, Ohio, United States

+ 9 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02905565